[Mildronate in geriatric patients with cardiac failure].

Abstract

AIM:

To study efficacy of mildronate in the treatment of elderly patients with cardiac failure (CF).

MATERIAL AND METHODS:

A total of 91 patients with chronic CF (NYHA FC I-III) entered the study. The study group of 63 patients received standard therapy for a month and mildronate in a dose 750 mg/day. The control group of 28 patients was treated conventionally. Subjective and objective assessment of the patients' condition, quality of life questionnaire, ECG, 6-min walk test were used for evaluation of the treatment efficacy.

RESULTS:

In the study group daily frequency of anginal attacks reduced from 1.6 to 0.7 (in the control group from 1.46 to 1.25, p > 0.05), intensity of the attacks--from 1.4 to 0.7 points by 7-score scale (p < 0.05). Crepitation disappeared in 8 (12.8%) patients, edema of the legs--in 3 (4.8%) patients. Systolic blood pressure went down by 8 mmHg, diastolic one--by 4 mmHg. In the control group clinical changes were insignificant.

CONCLUSION:

Elderly patients tolerated mildronate well. It was a safe drug attenuating CF symptoms, increasing exercise tolerance and improving quality of life.

• Authors: I Kalvinsh, A Visokinskas, G Bagdonas, Iu Knasene, V Lesaukaite, Iu Matsiyauskene
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 78 Issue 9 Pg. 75-7 ( 2006) ISSN: 0040-3660 [Print] Russia (Federation)
• PMID: 17076229 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Cardiovascular Agents
• Methylhydrazines
• 3-(2,2,2-trimethylhydrazine)propionate

Topics

• Age Factors
• Aged
• Aged, 80 and over
• Blood Pressure (drug effects)
• Cardiovascular Agents (therapeutic use)
• Female
• Follow-Up Studies
• Heart Failure (drug therapy, physiopathology)
• Humans
• Male
• Methylhydrazines (therapeutic use)
• Middle Aged
• Myocardial Contraction (drug effects)
• Quality of Life
• Treatment Outcome